Topic summary

Why catalogue breadth is not evidence of anything — what changed since

Compounds › Other compounds custom synthesis mislabelling needs a source research use only

This is a generated summary. It shows the 9 most-liked posts from a topic of 67, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

n.ekstromTL2Regular14 Jul 2025#1

Asking directly, because I could not find a straight answer: Why catalogue breadth is not evidence of anything — what changed since

What changes if the standard account of catalogue breadth is wrong? I ask because I have been treating it as settled and I noticed this week that I could not say why.

Working through the consequences rather than the evidence, since others here are better placed on the evidence.

58 likes 12mo

r.aldana_pharmdTL4Pharmacist27 Jul 2025 · edited#7

lc_gradient, post #5: This is the sort of exchange that makes the archive worth searching. Go to post

Genuine question rather than a rhetorical one: has anyone here actually observed catalogue breadth, as opposed to read about it? The thread is long and I cannot tell.

33 likes in reply to #5 12mo

two_year_lineTL3Regular6 Aug 2025#13

d.ferreira, post #12: Confirming post #11 from a second method, which matters more than confirming it from a second person. How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is… Go to post

I had read the opposite somewhere and cannot now find where, which tells me something.

27 likes in reply to #12 12mo

j.habermannTL3Regular27 Aug 2025#29

Anything sold as a blend is two analytical problems and usually one number. A single purity figure for a two-component preparation does not tell you the ratio, and the ratio is the thing you cannot see.

That is the honest state of it as of this week.

31 likes 11mo

l.lundgrenTL27 Sep 2025#38

week_three, post #25: This follows post #24 rather than contradicting it. A methods point on catalogue breadth rather than a substantive one: if the comparison is not like for like, the difference you are measuring is the difference in method. Go to post

Reading a supplier's product description as a marketing document: that is exactly what it is. The hyperbole, the mechanism written as fact, the theoretical benefits stated as established benefits — all of that is marketing. Treat it as such and separate it from evidence where evidence exists.

Posted with less confidence than the sentence structure implies.

27 likes in reply to #25 11mo

m.haddadTL2Regular16 Sep 2025#46

f.kimani, post #20: The bit of catalogue breadth that nobody enjoys is that the answer changes depending on what you are trying to decide with it. Say what the decision is and the thread will converge. Go to post

I changed my mind about catalogue breadth after someone here asked me for the source and I could not produce one. That is worth saying out loud because it is the ordinary way it happens.

25 likes in reply to #20 10mo

physio_marchettiTL2Physiotherapist24 Sep 2025#53

h.ramos, post #34: Narrowing post #33, because the general version has more than one answer. Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here. This is the sort of thing the wiki should carry and currently does not. Go to post

I have been on both sides of the catalogue breadth argument in this category within eighteen months, which should tell you how strong the evidence for either side is.

25 likes in reply to #34 10mo

e.coelhoTL25 Oct 2025#64

This subcategory exists because some people will research compounds outside the main groups discussed here. The standard of evidence and honesty about its limits applies to everything discussed, not just to approved drugs.

32 likes 10mo

GDashwoodTL3Regular9 Oct 2025#67

h.lindqvist, post #49: Narrowing post #46, because the general version has more than one answer. Two things can be true about catalogue breadth at once: the mechanism is plausible and the evidence for the size of the effect is thin. Most of the argument here is people defending the first against attacks on the second. Go to post

Post #64 is right about the mechanism and I think understates the practical bit.

A compound with no established assay is a compound where a certificate can say almost anything. That is not an accusation about anyone; it is a statement about what a document can carry.

Old habit: I write down the expected answer before I calculate it.

23 likes in reply to #49 10mo

Read the full topic (67 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
Compounds this community declines to help with, and why — does this still hold? Compounds › Other compounds custom synthesis research use only mislabelling Compounds this community declines to help with, and why — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Putting the numbers in the first post,…	+3	7	26k	7h
Sequence verification for an obscure compound: how it is done Compounds › Other compounds needs a source custom synthesis research use only mislabelling Sequence verification for an obscure compound: how it is done Writing it up because I had to work it out twice and would rather nobody else did. Asking about sequence verification directly, because I have…	+104	114	10k	12mo
Sequence verification for an obscure compound: how it is done — what changed since Compounds › Other compounds custom synthesis needs a source mislabelling On the subject in the title: Sequence verification for an obscure compound: how it is done — what changed since Working notes rather than a conclusion. What changes if the standard account of Sequence…	+100	108	1.3k	8mo
When "no data" is the complete and final answer Compounds › Other compounds custom synthesis mislabelling needs a source research use only Solved Asking directly, because I could not find a straight answer: When "no data" is the complete and final answer Asking about the compound itself rather than about a trial of it. I have read the maintained page…	+154	165	6.3k	15mo
Research-use-only status: what it means legally and practically — does this still hold? Compounds › Other compounds custom synthesis mislabelling needs a source research use only Solved Pinned Asking directly, because I could not find a straight answer: Research-use-only status: what it means legally and practically — does this still hold? Asking about Research-use-only status directly, because I…		2	309	9mo

Related topics — sharing the tags custom synthesis, mislabelling, needs a source

Topic	Participants	Replies	Views	Activity
What would change my mind about repair peptides: a specific answer — one year on Compounds › Repair & healing peptides needs a source observational data TB-500 preprint Closed What would change my mind about repair peptides: a specific answer — one year on I have a specific reason for asking rather than idle curiosity, and the context is below. Documentation question rather than a…	+9	13	42k	19mo
About the Payments category Sourcing › Payments payments research use only documentation quality Pinned Wiki Payment mechanics, chargeback reality, and the recurring risks. No payment facilitation of any kind here. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…		4	3.5k	20mo
Follow-up: Why we hide unevidenced fraud accusations and log the hiding Sourcing › Red flags mislabelling disputed moderation underdosing The question in the title: Why we hide unevidenced fraud accusations and log the hiding I will give what I have already checked below so nobody repeats it. Filing a documentation observation rather than a…	+12	16	17k	12mo
TB-500 and thymosin beta-4: the fragment versus the protein — does this still hold? Compounds › Repair & healing peptides TB-500 BPC-157 needs a source Closed TB-500 and thymosin beta-4: the fragment versus the protein — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Two things I would like separated…	+19	23	4.2k	19mo
Follow-up: Reading an interaction checker output critically Practice › Interactions insulin hypoglycaemia delayed gastric emptying needs a source Solved Reading an interaction checker output critically — setting out what I have, and where I think it stops being reliable. A follow-up question about Reading an interaction checker output that I did not know to…	+62	66	13k	2d